CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Miplyffa (arimoclomol) and Aqneursa (levacetylleucine) for Niemann-Pick disease type C — Coverage Criteria

Covers authorization, continuation, and quantity limits for Miplyffa and Aqneursa for treatment of neurological manifestations of Niemann-Pick disease type C (NPC) when specified clinical criteria are met; applies to members of Neighborhood Health Plan of Rhode Island.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyMiplyffa and Aqneursa for Niemann-Pick disease type C — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective Date

Next Review Date

Key ActionObtain prior authorization with documentation of baseline 5-domain NPCCSS, diagnostic confirmation, neurologic manifestations, and required weight/age and combination-therapy information.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

6 monthsauthorization duration

5-domain NPCCSSseverity scale required

≤3/dayMiplyffa quantity limit

≤4/dayAqneursa quantity limit

2–64 yrsAge limits (where specified)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage and Medical Necessity Criteria

inv-01: Initial authorization for NPC

Authorization for 6 months may be granted when ALL of the following are met:

Initial approval criteria: A. Documentation (e.g., chart notes) of baseline 5-domain NPCCSS assessment to establish baseline score; B. Documentation that diagnosis is confirmed by either (a) genetically confirmed variant in both alleles of NPC1 or NPC2 OR (b) mutation in only one allele of NPC1 or NPC2 plus either positive filipin staining or elevated cholestane-triol level (>2× ULN); C. Medical records documenting neurological manifestations of disease (e.g., loss of fine motor skills, swallowing, speech, ambulation); D. Stable on miglustat (e.g., Opfolda) for 6 months unless miglustat is not recommended for specified exceptions (advanced neurological disease and/or dementia, early‑infantile NPC, or splenic/hepatic enlargement only); E. Member has ability to walk independently or with assistance; F. Medication prescribed by or in consultation with an endocrinologist, geneticist, neurologist, or physician who specializes in metabolic/lysosomal storage disorders; G. Product-specific age/weight and combination restrictions apply (see product-specific criteria).

See product-specific child nodes for Aqneursa and Miplyffa

inv-02: Product-specific criteria — Aqneursa

Additional ALL requirements when request is for Aqneursa:

Aqneursa criteria: a. Member is 4 to 64 years of age; b. Documentation that member weighs ≥15 kg and prescribed dose is in accordance with FDA‑approved labeling based on current weight; c. The requested medication will not be used in combination with Miplyffa (arimoclomol) for treatment of NPC.

Aqneursa dosing and quantity limits specified in Quantity Limit section

inv-03: Product-specific criteria — Miplyffa

Additional ALL requirements when request is for Miplyffa:

Miplyffa criteria: a. Member is 2 to 19 years of age; b. Member does NOT have adult-onset NPC (defined as first neurological symptom >15 years of age); c. Documentation of current weight and prescribed dose in accordance with FDA‑approved labeling; d. The requested medication will be used in combination with miglustat (e.g., Opfolda); e. The requested medication will not be used in combination with Aqneursa (levacetylleucine) for treatment of NPC.

Miplyffa quantity limits and age limits specified in Quantity Limit section

inv-04: Continuation (Reauthorization)

Authorization of 6 months may be granted for continued treatment when ALL of the following are met:

Continuation criteria: A. Member continues to meet the criteria for initial approval; B. Documentation that member is experiencing benefit from therapy (e.g., stabilization or improvement in 5‑domain NPCCSS score, fine motor skills, swallowing, speech, ambulation).

Follow baseline NPCCSS comparison per clinical documentation

All indications for Miplyffa or Aqneursa that are not listed as FDA-approved or supported by compendial uses are considered experimental/investigational and not medically necessary.

Use of Miplyffa or Aqneursa for any indication other than the specified FDA‑approved indication for Niemann‑Pick disease type C (NPC) is considered not medically necessary.

Dosing Groups and Quantity Limits

Documentation Required

Provider Action: Required Clinical Documentation and Weight/Dose/Combination Therapy Requirements

Documentation must include current weight, prescribed dose, and evidence that dosing aligns with FDA‑approved labeling and the weight‑based dosing groups. For Miplyffa requests, include documentation that the medication will be used in combination with miglustat (e.g., Opfolda). For Aqneursa requests, include documentation that the medication will not be used in combination with Miplyffa. Attach clinical records supporting diagnosis, NPCCSS baseline when applicable, and any prior therapy (e.g., miglustat) as required by the coverage criteria.

Required clinical documentation: chart notes confirming diagnosis (genetic testing or diagnostic studies), NPCCSS baseline score, neurological manifestations, and specialty prescriber involvement.
Weight and dose documentation: current weight (kg) and prescribed dose that matches the weight‑based dosing table; specify route (oral vs G‑tube) if applicable.
Combination therapy requirement for Miplyffa: Miplyffa must be used in combination with miglustat; do not request concurrent Miplyffa and Aqneursa for the same indication.
Combination therapy prohibition for Aqneursa: Aqneursa must not be used in combination with Miplyffa for treatment of neurological manifestations of Niemann‑Pick disease type C.

Authorization, Documentation, and Prescribing Requirements

Prior Authorization

Prior authorization required with specified clinical documentation

Prior authorization is required for Miplyffa or Aqneursa for treatment of Niemann‑Pick disease type C and the request must include documentation of a baseline 5‑domain NPCCSS, diagnostic confirmation, documentation of neurological manifestations, miglustat stability when applicable, walking ability, specialty prescriber, and applicable age/weight and combination‑therapy restrictions.

Baseline 5‑domain NPCCSS assessment (chart notes) to establish baseline score.
Diagnostic confirmation per policy (see Diagnostic Confirmation block).
Documentation member is stable on miglustat for 6 months when required or applicable exceptions noted.

Step Therapy

Miplyffa must be prescribed in combination with miglustat (unless exceptions apply)

Requests for Miplyffa must document that therapy will be used in combination with miglustat (e.g., Opfolda) unless miglustat is not recommended due to advanced neurological disease, dementia, early‑infantile NPC, or when spleen/liver enlargement only is present.

Clinical Definitions and Scales

5-domain NPCCSS — Baseline and monitoring

Scale descriptionClinician-scored 5-domain NPCCSS assessing ambulation, fine motor, swallow, cognition, and speech; total score is the sum of domain scores (range 0–25; higher = greater impairment)

Baseline requirementDocumentation of a baseline 5-domain NPCCSS assessment (chart notes) is required at initiation to establish severity

Monitoring requirementFor continuation, documentation of benefit (stabilization or improvement in NPCCSS score or clinical signs) is required to support reauthorization

Source/AdaptationNPCCSS table adapted from Patterson et al.; domain-level scoring described in policy tables

Adult-onset NPC (per policy) — impact on Miplyffa eligibility

Definition

Clinical Background

Niemann‑Pick disease type C (NPC) is a rare lysosomal storage disorder characterized by progressive neurological manifestations. Clinically relevant features include decline in fine motor skills, difficulties with swallowing and speech, and impaired ambulation. The two products addressed by this policy—Miplyffa (arimoclomol) and Aqneursa (levacetylleucine)—are indicated specifically for the treatment of these neurologic manifestations of NPC in FDA‑specified age and weight groups.